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a b s t r a c t
Oxidative stress including DNA damage, increased lipid and protein oxidation, are important features of
aging and neurodegeneration suggesting that endogenous antioxidant protective pathways are inade-
quate or overwhelmed. Importantly, oxidative protein damage contributes to age-dependent accumula-
tion of dysfunctional mitochondria or protein aggregates. In addition, environmental toxins such as
rotenone and paraquat, which are risk factors for the pathogenesis of neurodegenerative diseases, also
promote protein oxidation. The obvious approach of supplementing the primary antioxidant systems
designed to suppress the initiation of oxidative stress has been tested in animal models and positive
results were obtained. However, these ﬁndings have not been effectively translated to treating human
patients, and clinical trials for antioxidant therapies using radical scavenging molecules such as α-
tocopherol, ascorbate and coenzyme Q have met with limited success, highlighting several limitations to
this approach. These could include: (1) radical scavenging antioxidants cannot reverse established
damage to proteins and organelles; (2) radical scavenging antioxidants are oxidant speciﬁc, and can only
be effective if the speciﬁc mechanism for neurodegeneration involves the reactive species to which they
are targeted and (3) since reactive species play an important role in physiological signaling, suppression
of endogenous oxidants maybe deleterious. Therefore, alternative approaches that can circumvent these
limitations are needed. While not previously considered an antioxidant system we propose that the
autophagy-lysosomal activities, may serve this essential function in neurodegenerative diseases by
removing damaged or dysfunctional proteins and organelles.
& 2014 The Authors. Published by Elsevier B.V. All rights reserved.
Contents
Introduction. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 83
Endogenous oxidants in aging and neurodegenerative disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 83
Endogenous antioxidants in aging and neurodegenerative disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 83
Oxidants and antioxidants in familial Parkinson’s disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84
Oxidants and antioxidants in neurotoxin-induced Parkinson’s disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84
Effects of antioxidants in animal models and human clinical trials . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84
Contents lists available at ScienceDirect
journal homepage: www.elsevier.com/locate/redox
Redox Biology
2213-2317/$ - see front matter & 2014 The Authors. Published by Elsevier B.V. All rights reserved.
http://dx.doi.org/10.1016/j.redox.2013.12.013
Abbreviations: 6-OHDA, 6-hydroxydopamine; the ADAGIO study, the Attenuation of Disease Progression with Azilect Given Once-daily) study; CBZ, carbamazepine;
curcumin, (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione; the DATATOP Study, the Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism
Study; EGCG, epigallocatechin gallate; GSH, glutathione; HIF1α, hypoxia-inducible factor 1-alpha; HNE, 4-hydroxynonenal; iPSC, induced pluripotent stem cells; LRRK2,
leucine-rich repeat kinase 2; MDA, malondialdehyde; MnSOD, manganese superoxide dismutase; MitoQ, mitochondrially-targeted coenzyme Q; MPPþ , 1-methyl-4-
phenylpyridinium; MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydro pyridine; the NET-PD network, the NINDS Exploratory Trials in Parkinson’s Disease (NET-PD) network;
Nrf2, Nuclear factor (erythroid-derived 2)-like 2; PINK1, PTEN-induced putative kinase 1; rasagiline, N-propargyl-1-(R)-aminoindan; ROS/RNS, reactive oxygen and nitrogen
species; SOD, superoxide dismutase; Selegiline, N-propargyl-methamphetamine; Sirt1, NAD-dependent deacetylast sirtuin-1; the TEMPO Study, the TVP-1012 in Early
Monotherapy for PD Outpatients Study; TFEB, transcription factor EB; UCHL1, ubiquitin carboxyl-terminal hydrolase L1; UPDRS, Uniﬁed Parkinson’s Disease Rating Scale
☆This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike License, which permits non-commercial use,
distribution, and reproduction in any medium, provided the original author and source are credited.
n Corresponding author at: Department of Pathology, University of Alabama at Birmingham, Biomedical Research Building II, 90119th Street South, Birmingham, AL 35294,
United States. Tel.: þ205 996 5153; fax: þ205 934 7447.
E-mail address: zhanja@uab.edu (J. Zhang).
Redox Biology 2 (2014) 82–90
Effects of antioxidants in mammalian models of Parkinson’s disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84
Clinical trials . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85
Autophagy: a more effective antioxidant pathway for diverse mechanisms of oxidative damage in neurodegenerative diseases . . . . . . . . . . . . . . . . 86
Conclusions and future directions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 88
Acknowledgments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 88
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 88
Introduction
Neurodegenerative diseases affect millions of people each year
and the incidence is increasing with the aging of our populations.
It has been projected by the National Institutes of Health that by
2030 about one in ﬁve Americans over the age of 65 will be
diagnosed with a neurodegenerative disease [1]. Over the last
several decades a broad range of studies (summarized in Table 1)
have demonstrated that the progression of age-dependent neuro-
degeneration is associated with decreased antioxidants and
increased oxidative damage to proteins, DNA and lipids [2–4].
Oxidative protein modiﬁcation occurs at a low and persistent level
in diverse cells and tissues, and accumulates in aging and neuro-
degenerative diseases. Here we will review evidence of oxidative
damage in neurodegenerative diseases with a particular focus on
Parkinson’s disease, discuss effects and challenges of antioxidant
therapies in animal models and clinical trials. Finally, we will
propose the hypothesis that the autophagy-lysosomal pathway
provides a distinct new class of antioxidant mechanisms which
have a therapeutic potential.
Endogenous oxidants in aging and neurodegenerative disease
Mammalian brains have a high propensity to generate reactive
oxygen and nitrogen species (ROS/RNS) including hydrogen peroxide,
superoxide, nitric oxide and peroxynitrite [5–10]. The high rate of O2
consumption by mitochondrial metabolism in the brain and the
constant supply of oxygen allow for ROS/RNS to be generated from a
variety of sources including nitric oxide synthases and from the
mitochondrial respiratory chain [7–10]. These processes are further
enhanced by neuroinﬂammation in which glia cells become an
additional source of ROS from NADPH oxidases [10,11]. The brain also
contains high levels of polyunsaturated fatty acids which are targets
for the initiation of lipid peroxidation which can propagate the
formation of reactive lipid species such as 4-hydroxynonenal (HNE)
and malondialdehyde (MDA) which in turn are capable of modifying
proteins [12–14]. These covalent modiﬁcations of proteins appear to
accumulate in the brain during aging and in Alzheimer’s and
Parkinson’s diseases [15,16]. It should be noted that HNE is only one
of several reactive lipid species that are produced during non-speciﬁc
lipid peroxidation and should be considered as a representative of this
class of molecules. Using the less speciﬁc protein carbonyl measure-
ment protein oxidation has also been found to be increased in post-
mortem Parkinson’s disease brains compared to controls [17]. Speciﬁc
proteins which have been shown to be oxidized include mitochondrial
electron transport complex I subunits [18], ubiquitin carboxyl-terminal
hydrolase L1 [19], and DJ-1 [20], all of which have been implicated in
familial or sporadic Parkinson’s disease.
A major contributor to the pro-oxidant environment in the brain
is thought to be peroxynitrite which is formed from the reaction of
superoxide and nitric oxide [7]. Consistent with the formation of
peroxynitrite, nitration of α-synuclein is increased in Lewy bodies
and Lewy neurites in several synucleinopathies [6,21,22]. It is
important to note that peroxynitrite can promote protein and lipid
oxidation/nitration independently. This ﬁnding implies that the
targeting of lipid peroxidation by scavengers such as α-tocopherol,
ascorbate and coenzyme Q10 would be ineffective if the patholo-
gical mechanism of neurodegeneration involves protein oxidation
independent of the reactive lipid species. Both nuclear and mito-
chondrial DNA damage are also associated with aging [23] and
neurodegenerative diseases, such as Parkinson’s [24,25] and Alzhei-
mer’s disease [26]. Therefore, both lipid peroxidation-dependent
and independent mechanisms may be involved in cellular damage
occurring in neurodegenerative diseases.
Endogenous antioxidants in aging and neurodegenerative disease
The antioxidants produced endogenously, including superoxide
dismutases (SOD), catalases, peroxiredoxins, and glutathione, play
Table 1
Oxidative damage in Parkinson’s disease. Evidence from postmortem studies of aging and neurodegenerative disease and control brains indicate that lipid, protein and DNA
damage are higher in aging and disease brains, and supports the hypothesis that oxidative damage promotes neurodegeneration.
Ref
Evidence of oxidative damage in sporadic Parkinson’s disease
HNE-protein adducts are increased in Alzheimer’s and Parkinson’s disease brains [15,16]
Protein carbonyl accumulation in Parkinson’s disease brain [17]
Oxidized proteins complex I subunits, ubiquitin carboxyl-terminal hydrolase L1, and DJ-1 [18–20]
Nitration of α-synuclein in synucleinopathies [21]
Nuclear and mitochondrial DNA damage in aging, Parkinson’s and Alzheimer’s diseases [23–26]
Lower glutathione in aging and Parkinson’s disease brain [31–33]
Plasma levels of ascorbate and α-tocopherol are lower in vascular but not non-vascular Parkinson’s disease patients [39]
Coenzyme Q10 redox ratio is decreased in platelets of Parkinson’s disease patients [40]
Increases of thiol-DOPA conjugates in substantia nigra of Parkinson’s disease brains [41]
Evidence of oxidative damage in familial Parkinson’s disease
Increased heme oxygenase 2 and monoamine oxidase expression in differentiated dopaminergic neurons
from patient derived induced pluripotent stem cells (iPSC)
[44]
Neuronal cells from dominant Parkinson’s disease mutant LRRK2 G2010S iPSCs exhibit higher mitoSOX staining [45]
Fibroblasts from Parkinson’s disease patients with PINK1 mutations exhibit increased mitochondrial ROS [46]
Mitochondrial DNA lesions are increased in neural cells from iPSCs carrying LRRK2 mutations [47]
Lower glutathione in Parkin mutant iPSC neurons [48]
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important roles in preventing endogenous and xenobiotic-induced
oxidative damage [27]. Glutathione, the endogenously produced,
thiol containing tri-peptide, plays an important role in antioxidant
defense and redox homeostasis, and is found at lower levels in
neurons compared to astrocytes [28,29], and is also lower in the
substantia nigra compared to cortex [30]. In the brain, decreased
glutathione levels have also been reported in aging [31] and sporadic
Parkinson’s disease [32–38]. Plasma levels of ascorbate and α-
tocopherol have been reported to be lower in vascular but not
non-vascular Parkinson’s disease patients [39]. The coenzyme Q10 is
more oxidized in platelets of Parkinson’s disease patients consistent
with increased mitochondrial oxidative stress [40]. In support of
increased DOPA oxidation and subsequent conjugation with thiol
compounds, the speciﬁc products 5-S-cysteinyl-dopamine, 5-S-
cysteinyl-DOPA and 5-S-cysteinyl-DOPAC, have been found to be
increased in substantia nigra of Parkinson’s disease brains [41].
Oxidants and antioxidants in familial Parkinson’s disease
There is considerable evidence that redox-dependent changes
also occur in familial Parkinson’s disease. Although most cases are
sporadic, about 10% of Parkinson’s disease cases are due to genetic
causes [42,43]. Differentiated dopaminergic neurons from patient-
derived induced pluripotent stem cells (iPSCs) with α-synuclein
gene triplication exhibited increased heme oxygenase 2 and
monoamine oxidase expression compared to control cells [44].
Neuronal cells from iPSC of Parkinson’s disease patients carrying
mutant LRRK2 G2010S and ﬁbroblasts carrying PINK1 mutations
have been found to exhibit higher mitochondrial superoxide
formation [45,46]. Mitochondrial DNA lesions are increased in
neural cells from iPSCs carrying LRRK2 mutations [47]. In Parkin
mutant iPSC neurons, glutathione levels have been found to be
lower while Nrf2 levels are higher compared to controls, suggest-
ing an impairment in the engagement of the endogenous Keap1-
Nrf2 antioxidant protective pathways [14,48].
Oxidants and antioxidants in neurotoxin-induced Parkinson’s disease
Supporting the hypothesis that oxidants contribute to the
pathophysiology of neurodegenerative disease, it has been shown
that many of the neurotoxins that increase Parkinson’s disease
risk or parkinsonism in humans and animal models also induce
oxidant production and promote oxidative damage (Table 2).
The neurotoxin MPTP causes parkinsonism in humans by entering
astrocytes where it is converted to the active metabolite MPPþ by
monoamine oxidase-B. MPPþ is then taken up by the dopaminergic
neurons via the dopamine transporter, and causes degeneration of
these neurons [49]. It has been reported that MPPþ can bind and
inhibit complex I of the mitochondrial respiratory chain, and increase
production of superoxide in a complex I-dependent mechanism,
although cellular toxicity may be mediated through ROS and complex
I-independent mechanisms [50,51]. MPTP administration in mouse
models has been shown to increase mitochondrial and nuclear DNA
damage [52], and 2,3-dihydroxbenzoic acid (2,3-DHB), a marker of
hydroxyl radical formation. Although there is evidence for an adaptive
response such as increased antioxidant enzyme activities, including
those of glutathione peroxidase, superoxide dismutase, and catalase,
in the midbrain, dopaminergic neurodegeneration still proceeds. This
indicates that the increase of antioxidant enzymes is insufﬁcient for
neuroprotection during the progression of Parkinson’s disease [53].
Other environmental toxins including pesticides, such as rote-
none and paraquat, have been associated with increased risk of
developing Parkinson’s disease [54]. Rotenone, a complex I inhi-
bitor, administrated in animal models induces dopaminergic
neurodegeneration, accumulation of DNA damage [55], increased
nitric oxide [56], lipid peroxidation products [56], and protein thiol
modiﬁcation [57–60]. Although the herbicide paraquat exhibits
structural similarity to MPPþ , it appears to act through redox
cycling rather than inhibition of complex I and induces dopami-
nergic neurodegeneration [61–63]. Paraquat exposure in rats has
been shown to decrease glutathione, decrease reduced coenzyme
A, and increase 3-nitrotyrosine [64].
6-OHDA is a naturally occurring by-product of dopamine
synthesis and has been found in human brains and urine [65].
As with MPTP and rotenone, 6-OHDA administration in animals
also induces dopaminergic cell death, movement disorders, accu-
mulation of DNA damage [66], increased malonaldialdehyde levels
[67], and protein carbonyls [68]. However, the mechanisms appear
unrelated to mitochondrial dysfunction and may involve other
pro-oxidant mitochondrial-independent pathways [51,68].
Effects of antioxidants in animal models and human clinical
trials
The current treatment of Parkinson’s disease is limited to
relieving symptoms, without any signiﬁcant effects in slowing
the neurodegenerative processes. Because oxidative damage may
contribute signiﬁcantly to neurodegeneration in human patients
and animal models, the idea of antioxidant therapy has been
tested in animal models, followed by clinical trials in Parkinson’s
disease patients.
Effects of antioxidants in mammalian models of Parkinson’s disease
Numerous studies using rat, mouse or primates have tested the
efﬁcacy of neuroprotective interventions by low molecular weight
Table 2
Oxidative damage in toxin models of Parkinson’s disease. Evidence of oxidative damage and effects of antioxidant are summarized from studies in toxin models of
Parkinson’s disease.
Toxins Oxidative damage in animal models Ref Protective effects of antioxidants Ref
MPTP MPTP administration increases mitochondrial and nuclear
DNA damage, and markers of hydroxyl radicals
[52,53] α-tocopherol, β-carotene, ascorbic acid, selegiline, creatine,
ebselen, coenzyme Q, lipoic acid, N-acetyl-cysteine, lipoic acid,
EGCG, edaravone
[69–
75,77,78]
Rotenone Rotenone administration increased nitric oxide, lipid
peroxidation
products, and protein thiol modiﬁcation
[56–59] N-acetyl-cysteine-related compound, edaravone [77,79]
Paraquat Paraquat exposure decreased glutathione, decreased
reduced coenzyme A,
and increased 3-nitrotyrosine/tyrosine levels
[64]
6-OHDA 6-OHDA administration increases DNA damage,
malonaldialdehyde levels,
lipid peroxidation products and protein carbonyls
[66–68] N-acetyl-cysteine-related compound, edaravone, resveratrol [68,77,80]
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antioxidants. Here we will highlight some of the antioxidant studies
which have shown neuroprotective effects in MPTP, rotenone and
6-OHDA-induced neurodegeneration models (Table 2).
In an acute MPTP administration mouse model, high doses of
α-tocopherol, β-carotene, ascorbic acid or N-acetyl-cysteine, all
decreased MPTP-induced striatal dopamine loss [69]. Additional
studies have shown that a variety of compounds with antioxidant
properties such as selegiline [70], creatine [71], ebselen [72],
coenzyme Q [73], EGCG [74], and lipoic acid [75] provide protec-
tion in MPTP administration-induced neurodegeneration models.
It is important to note that many of these compounds have other
properties and it should not be assumed that radical scavenging is
their primary mode of action. For example, although it has been
shown that creatine has antioxidant activity in in vitro models the
physiological relevance of these tests is open to question and the
concentrations required for a signiﬁcant effect are higher than
those that can be achieved biologically [76].
In addition to MPTP models, effects of antioxidants have also
been tested in animal models of rotenone or 6-OHDA-induced
neurodegeneration. For example, a small molecular weight N-
acetyl-cysteine-related compound AD4 [77], and 3-methyl-1-
phenyl-2-pyrazolin-5-one (edaravone) [78–80] have been shown
to decrease nigrostriatal degeneration. Oral N-acetyl-cysteine,
which modulates thiol signaling and can act as a glutathione
precursor, also attenuates neurodegeneration in alpha-synuclein
overexpressing mice [81]. Although all of these toxic inducers of
Parkinsonism are associated with changes in non-speciﬁc mar-
kers of oxidative stress, the detailed mechanisms are not
the same.
Clinical trials
Although antioxidant treatments have shown neuroprotective
potential in mammalian models of Parkinson’s disease in which it
is induced by a deﬁned toxin administered in a pure form, human
clinical trials have not been as successful. In the section below we
will highlight some of the antioxidant clinical trials (Table 3).
The DATATOP (Deprenyl and Tocopherol Antioxidative Therapy of
Parkinsonism) trial was one of the ﬁrst large clinical trials asses-
sing the effects of α-tocopherol and selegiline (N-Propargyl-
methamphetamine), a monoamine oxidase B (MAO-B) inhibitor,
in neuroprotection, with 800 patients randomized with treatment
for up to 2 years [82,83]. In this study, selegiline but not α-
tocopherol has improved the initial Uniﬁed Parkinson’s Disease
Rating Scale (UPDRS) score, which rates both motor and mentation
scores by patients and clinicians, and delayed the time of onset of
the clinical decision for L-dopa treatment.
A more potent MAO-B inhibitor rasagiline (N-propargyl-1-(R)-
aminoindan) has also been shown to have effects in the TEMPO
(TVP-1012 in Early Monotherapy for PD Outpatients) study with
404 patients [84]. The patients were either treated with placebo or
rasagiline for the ﬁrst 6 months followed by rasagiline treatment
for all subjects for the subsequent 6 months. The early-start
rasagline group had an enduring beneﬁt as reﬂected by improved
UPDRS scores compared to the placebo group. Following the
TEMPO study, a larger study, the ADAGIO (Attenuation of Disease
Progression with Azilect Given Once-daily) study with 1176
patients for an initial 36 weeks rasagiline versus placebo, all
followed by rasagiline for subsequent 36 weeks, again supported
Table 3
Clinical trials of antioxidant therapies in Parkinson’s disease (PD).
Trial name Antioxidants Patients Type of Clinical Trial Findings Citation
DATATOP Selegiline: MAO-B inhibitor;
Tocopherol: peroxyl radicals
and lipid peroxidation
products
Stage 1 and 2 PD patients with
no treatment for PD
(800 patients)
Randomized, double-blind,
placebo-controlled, multi-center
Selegiline but not tocopherol slows
onset of clinical decisions of needing
L-DOPA
[82,83]
TEMPO Rasagiline: more potent
MAO-B inhibitor than
selegiline
Early PD patients who did not
require treatment
(404 patients)
Delayed-start, 6 months placebo
versus rasagiline, all followed by
rasagiline, double-blind, placebo-
controlled clinical trial
Rasagiline is effective in improving
UPDRS scores
[84]
ADAGIO Rasagiline: more potent
MAO-B inhibitor than
selegiline; also found to boost
antioxidant production
Untreated PD (1174 patients) Double blind, delayed-start trial, 36
weeks of placebo versus rasagiline,
all followed by rasagiline
Rasagiline is effective in improving
UPDRS scores
[85,86]
Creatine Creatine (increases cellular
energy, antioxidant)
PD patients who did not
require MAO inhibitors
(60 patients)
Placebo controlled randomized
pilot study
No change in UPDRS or SPECT scores
compared to control subjects after 2 yr
treatment.
[87]
Creatine Creatine (increases cellular
energy, antioxidant)
PD patients over 30 who did
not require medication
(200 patients)
Randomized, double blind, futility
clinical trial-Phase II
Both creatine and minocycline showed
moderate protection of UPDRS, and
should be considered for Phase III
clinical trials
[88]
Creatine LS-1
NET-PD
Creatine (increases cellular
energy, antioxidant)
1741 patients Phase III No statistical difference between
placebo and creatine, trial terminated
[89]
NINDS
website
Coenzyme
Q10–QE2
Coenzyme Q10 (antioxidant in
mitochondria and lipid
membranes)
Early PD patients who did not
require treatment (80 patients)
Multicenter, randomized, parallel-
group, placebo controlled, double-
blind, dosage ranging trial
CoQ10 preserved UPDRS and increased
time to levodopa treatment, especially
in the highest dose of CoQ10
[90]
CoenzymeQ10 Coenzyme Q10 (antioxidant in
mitochondria and lipid
membranes)
PD patients over 30 who did
not require medication
(71 patients each in placebo
and CoQ10 groups)
Randomized, double blind, futility
clinical trial–Phase II
Although CoQ10 cannot be rejected as
futile, the improvement of UPDRS was
not signiﬁcant, Phase III clinical trials
was recommended
[91]
Coenzyme
Q10—QE3
Coenzyme Q10 (antioxidant in
mitochondria and lipid
membranes)
600 patients with early
Parkinson’s disease
Phase III trial with 1200mg/day and
2400mg/day for up to 16 months of
treatment
Trial terminated due to lack of effect NINDS
website
MitoQ MitoQ (mitochondrial
antioxidant)
Newly diagnosed PD patients
(128)
Double blind, placebo controlled
study
MitoQ did not slow disease progression
or preserve UPDRS score
[93]
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a positive effect of the drug [85,86]. It is important to note that
improvement of the UPDRS score and clinical measures do not
necessarily reﬂect disease-modiﬁcation, currently strong evidence
supporting disease modiﬁcation effects of these drugs is still
lacking.
Creatine supplementation was also tested in clinical trials,
with one trial failing to show a beneﬁcial effect of creatine in
improving UPDRS scores or dopamine transporter SPECT vari-
ables which characterize dopaminergic cell loss [87], whereas
another trial observed improvement in UPDRS [88]. The long-
term Study-1 (LS-1) phase III trial of creatine by the NINDS
Exploratory Trials in Parkinson’s Disease (NET-PD) network with
1741 patients was recently terminated due to lack of statistically
signiﬁcant difference between creatine and placebo, although a
detailed analysis of the complete data set has not been published
to our knowledge [89].
Another compound tested in clinical trials is the coenzyme
Q10. Coenzyme Q10 is required for mitochondrial bioenergetics
and can inhibit lipid peroxidation in mitochondrial mem-
branes. Its effects in delaying the progression of Parkinson’s
disease showed promising early results which could be con-
ﬁrmed in later trials [90,91]. To improve the targeting of
coenzyme Q10 to the mitochondrion, the mitochondrially
targeted coenzyme (MitoQ) was synthesized, and shown to
be protective in the MPTP animal model [92,93], but ineffective
in a human trial [94].
As discussed above clinical trials using antioxidants in neuro-
degenerative diseases have generally proven ineffective. One
critical drawback of this approach is that the interception of
initiating oxidants cannot be completely efﬁcient, allowing slow
but persistent oxidative damage to occur. It is also important to
recognize that the majority of Parkinson’s disease patients do not
come to the clinic until there is extensive neurodegeneration. At
this point signiﬁcant damage, including oxidative damage of
proteins, DNA and organelles, has already occurred throughout
the brain, suggesting that endogenous antioxidant pathways are
already overwhelmed and antioxidant therapy alone cannot
reverse this damage.
The antioxidant therapies which have been tested have a
higher speciﬁcity towards lipid peroxidation as the pro-
oxidant pathway, but this may not be the most or the only
critical initiating mechanism. Antioxidants are generally spe-
ciﬁc for scavenging speciﬁc oxidants. For example, α-
tocopherol is effective at removing lipid peroxyl radicals, while
deprenyl is more effective at removing free radicals produced
from monoamine oxidase. Furthermore, enzymatic antioxi-
dants have even more speciﬁc oxidant targets. MnSOD is able
to dismutate O2- into H2O2 while glutathione and its associated
enzymes remove reactive aldehydes through conjugation and
peroxides through reduction. It follows that no single antiox-
idant therapy can efﬁciently neutralize all oxidants produced,
and it is then perhaps not surprising that efﬁcacy has been
limited. Furthermore, the lack of efﬁcacy of compounds, which
are effective in animal models, in human subjects could also be
due possibility that the mechanisms through which the
patients developed the disease were distinct from that pro-
duced in the models.
Finally, antioxidant therapies use very high doses of antiox-
idant which can potentially perturb physiological redox signaling.
As many studies demonstrated, redox signaling is important for
cellular function. Oxidants can regulate different activities, includ-
ing Keap1-Nrf2 signaling [95,96], and cellular differentiation [97].
Furthermore, antioxidant compounds such as the polyphenolics
can bind and reduce transition metal ions and then perturb redox
signaling within the cell through the formation of superoxide or
hydrogen peroxide [98].
Autophagy: a more effective antioxidant pathway for diverse
mechanisms of oxidative damage in neurodegenerative
diseases
As an alternative approach to antioxidant therapy with low
molecular weight compounds targeted at one mechanism we
propose that the autophagy pathway, which can clear previously
damaged proteins and organelles generated by diverse oxidants
without perturbing redox signaling, may achieve a more desirable
antioxidant effect in neurodegenerative diseases. Autophagy is
taken from the Greek words auto “self” phagy “eating” and was
coined by Christian De Duve in the 1960s [2,4,99]. The autophagy
pathway was ﬁrst discovered under nutrient starvation conditions
associated with mTOR inactivation [2,4,99]. Autophagy breaks
down macromolecules and recycles their components not only
to preserve cellular energy but also to clear damaged proteins and
mitochondria [2,4,99]. Autophagy of mitochondria can be regu-
lated by Parkin, PINK1 and DJ-1, and importantly mutations in
these proteins are thought to cause familial Parkinson’s disease
[2,4,99]. As discussed earlier, signiﬁcant accumulation of damaged
protein, lipid and DNA has been found in Parkinson’s disease,
indicating an insufﬁcient clearance of these modiﬁed molecules.
Genetic ablation of autophagy genes ATG5 and ATG7 has been
shown to cause neurodegeneration and abnormal accumulation of
cytoplasmic inclusion bodies [100,101]. Mouse brains or primary
neurons with deﬁciencies in Parkin, PINK1 and DJ-1 exhibited
mitochondrial abnormalities that may be due to insufﬁcient
mitophagy [102–104], increased protein oxidation and lipid per-
oxidation [105], increased mitochondrial or cytosolic reactive
oxygen species and mito-roGFP oxidation [103,104,106–108],
and increased sensitivity to neurotoxic or inﬂammatory insults
[109–111]. The strategy of upregulating autophagy to treat neuro-
degenerative diseases has been tested in various cell and animal
models and shown to decrease protein aggregation and cell death
(Table 4).
Rapamycin, an antifungal macrolide, was found to inhibit
mTOR activity and thereby stimulate autophagy. Upregulation of
autophagy with rapamycin in differentiated SH-SY5Y cells exposed
with rotenone preserved cell viability [112]. The protection by
rapamycin was ablated when the essential autophagy protein
Atg5 was knocked down [112]. In addition to rapamycin, mTOR
independent autophagy induction by lithium, valproic acid, or
carbamazepine (CBZ) in SH-SY5Y cells protected against rotenone-
induced cell death, whereas autophagy inhibition by chloroquine
exacerbated cell death [113]. Upregulation of autophagy by
trehalose in PC12 cells expressing either mutant huntingtin or α-
synuclein accelerated the clearance of protein aggregates [114].
Nutraceuticals may also modulate autophagy. This has been
suggested for the ﬂavonoid polyphenol EGCG, the non-ﬂavonoid
polyphenol curcumin ((1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphe-
nyl)-1,6-heptadiene-3,5-dione), and resveratrol [115–117]. These
compounds are clearly pleiotropic and have been reported to also
increase the levels or activities of HIF1α [118], Nrf2 [119] or Sirt1
[116]-mediated pathways.
Animal studies in neurodegenerative diseases using autophagy
upregulators have also shown positive results. Rapamycin and
trehalose have been shown to decrease protein aggregation and
pathology in animal models of amyotrophic lateral sclerosis,
Huntington’s, Alzheimer’s, and Parkinson’s diseases [120–125].
Trehalose in drinking water, in mice with both deletion of parkin
and transgenic overexpression of human mutated tau protein, was
able to increase autophagy, decrease the accumulation of Tau and
dopaminergic neuron death, and increase glutathione [120]. The
ability to upresulate glutathione levels supports the link between
autophagy and antioxidant defenses [120]. In contrast to rapamy-
cin, trehalose is free of toxic effects at high concentrations and has
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a long history of human use, supporting further examination of its
effects on Parkinson’s disease therapy.
In addition to pharmacological interventions, genetic activation
of autophagy has been tested in animal models and shown to exert
a neuroprotective role. In Parkinson’s disease mouse models, gene
therapy with Beclin 1, Parkin, DJ-1, and transcription factor EB
(TFEB) which is a master transcription activator of many autophagy-
lysosomal genes, was reported to protect against Parkinsonian
pathology [126–128]. Parkin transgenic mice are more resistant to
MPTP induced neurodegeneration and have decreased proportions of
vacuole-containing mitochondria or mitochondria with fragmented
cristae [128].
Table 4
Evidence that autophagy plays an antioxidant function by mitigating the effects of oxidative stress.
Model Evidence that upregulation of autophagy is neuroprotective Ref
SH-SY5Y cells Upregulation of autophagy with rapamycin protects against rotenone toxicity, this protection is
dependent on Atg5
[112]
SH-SY5Y cells Upregulation of autophagy by rapamycin, lithium, CBZ, or valproic acid decreased, while inhibition of
autophagy by chloroquine increased cell death and DCFH signals in response to rotenone
[113]
PC12 cells Upregulation of autophagy by trehalose helped clearing mutant huntingtin and α-synuclein [114]
Loss of function in ATG5 or ATG7
in mice
Abnormal accumulation of cytoplasmic inclusion bodies [100,101]
Loss of function in Parkin, PINK1
or DJ-1 in mice
Accumulation of abnormal mitochondria; Increased protein oxidation and lipid peroxidation; Increased
mitochondrial or cytosolic reactive oxygen species and mito-roGFP oxidation; Increased sensitivity to
neurotoxic or inﬂammatory insult
[102–105] [103,104]
[104,106–108] [109–111]
MPTP administration in mice Rapamycin decreased dopaminergic neurodegeneration [124]
parkin deleted human mutant
tau overexpressed mice
Trehalose decreased dopaminergic neurodegeneration [120]
Alpha-synuclein transgenic mice Beclin delivery is neuroprotective [126]
AAV-alpha-synuclein AAV-Beclin, AAV-TFEB or CCI-779 a rapamycin derivative, are neuroprotective [127]
MPTP administration in mice Parkin transgenic overexpression is neuroprotective [128]
6-OHDA-injected rats, rotenone
or MPTP treated mice
DJ-1-binding compounds, or direct delivery of DJ-1 protect against cell death induced by
6-hydroxydopamine, MPTP, or rotenone in rodents
[131–133]
Fig. 1. Autophagy as an antioxidant protective pathway. (A) Cells with increased ROS/RNS damage both proteins and mitochondria and propagate damage in neighboring
cells. Protein aggregates can cause more mitochondrial damage and damaged mitochondria can further induce protein damage, thus resulting in neurodegeneration.
(B) Lipid radical scavenging antioxidants cannot completely suppress lipid peroxidation or clear damaged proteins or organelles, and continued damage of biomolecules
occurs. Furthermore, at high levels antioxidants may disrupt normal redox signaling. (C) Through removing the initial damaged mitochondria and aggregated proteins,
autophagy can provide an effective antioxidant strategy independent of the initiating mechanism.
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DJ-1 is another multi-functional protein playing an essential
role in modulating autophagy [129], as well as a redox sensor
through modulatory cysteine residues [130]. Pre-clinical studies
of DJ-1-binding compounds, or direct delivery of DJ-1 have
been found to protect against oxidative stress-induced death of
neuroblastoma cells, primary mesencephalic cells, as well as
dopaminergic cells in 6-hydroxydopamine, MPTP, or rotenone-
exposed rodents [131–133]. The potential utility of therapeutic
drug screening which targets to proteins modiﬁable at cysteine
residues in response to oxidative stress is important and need to
be further explored. Furthermore, although it is hypothesized that
autophagy activation decreases the widespread propagation of
oxidative damage in neurons, most studies have focused on
demonstrating decreased accumulation of aggregation prone pro-
teins and cell death, without any direct examination of cellular
redox status or oxidative damage. Future mechanistic investiga-
tions of the effects of autophagy upregulation on the oxidative
damage of proteins, lipids, DNA or organelles in animal models of
Parkinson’s disease are needed.
Conclusions and future directions
In this article we have discussed the ﬁnding that despite
abundant evidence from both patients and experimental models
that oxidative damage occurs in neurodegenerative disease, anti-
oxidant therapy has been largely ineffective in clinical trials in
slowing disease progression. There may be several explanations
underlying these ﬁndings, including the diverse mechanisms of
pro-oxidant action in Parkinson’s disease pathology and the
advanced nature of the oxidative damage at the time of clinical
presentation. As shown in Fig. 1 we propose that rather than direct
scavenging oxidants, clearance of oxidative damage may be a more
effective strategy for the treatment of neurodegenerative diseases
(Fig. 1).
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